NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
Open Posted
- Opportunity number
- RFA-HL-26-003
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- Tribal Governments (Federally Recognized)
- Special District Governments
- For Profit Organizations
- Other
- State Governments
- Small Businesses
- Public or Indian Housing Auth.
- City/Township Governments
- County Governments
- 501(c)(3) Nonprofits
- Non-501(c)(3) Nonprofits
- Tribal Organizations (Not Federally Recognized)
- Independent School Districts
- Higher Education Inst. (Public)
- Higher Education Inst. (Private)
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health National Heart, Lung, and Blood Institute (NHLBI) seeks applicants for the Emerging Investigator Award (EIA) (R35 Clinical Trial Optional), a grant mechanism with an application deadline of April 28, 2027. Applicants must be experienced Program Directors/Principal Investigators currently holding at least two NHLBI R01-equivalent awards and demonstrating an outstanding record of research productivity in heart, lung, blood, and sleep (HLBS) science; this eligibility requirement substantially restricts the applicant pool to established, NHLBI-funded investigators.
The EIA supports a research program rather than a single research project, positioning it as the primary or sole source of NHLBI funding for the individual award. The mechanism provides up to seven years of support, granting investigators increased flexibility and freedom to pursue high-risk research, extend previous discoveries in new directions, or break new scientific ground. Research must remain within the NHLBI mission scope.
Eligible applicants include tribal governments (both federally recognized and non-federally recognized), state and local governments, public and private higher education institutions, small businesses, for-profit organizations, 501(c)(3) and non-501(c)(3) nonprofits, faith-based and community-based organizations, HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, Asian American Native American Pacific Islander serving institutions, tribally controlled colleges and universities, regional organizations, and U.S. territories and possessions. Non-domestic (non-U.S.) entities are not eligible to apply; however, foreign components of U.S. organizations are permitted as defined in the NIH Grants Policy Statement.
The program is assigned to four NHLBI Assistance Listings: Cardiovascular Diseases Research (CFDA 93.837), Lung Diseases Research (CFDA 93.838), Blood Diseases and Resources Research (CFDA 93.839), and Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (CFDA 93.840). All applications undergo initial review by an appropriate study section, followed by final secondary review and funding recommendations by the National Heart, Lung, and Blood Advisory Council. Standard NIH review timelines apply: 7 to 9 months from submission to award decision.
Synopsis
The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PDs/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00289029.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity